Q1 2024 revenue Quarterly activity Revenue: ‚194.3m, up 8.8% at CER1Growth remains particularly strong in Asia (+26.8% at CER) and the Americas (+20.1% at CER); the EMEA region (-6.2% at CER) was...
Financial agenda for 2024 Villepinte, 15 January 2024: Guerbet (FR0000032526), a global specialist in contrast agents and solutions for medical imaging, is announcing its financial agenda for 2024. ...
Revenue at 30 September 2023 Activity 9-month revenue: ‚¬573.9 million, up 2.7% at CER1 Third-quarter sales remained very strong in...
The CHMP issues an opinion in favour of granting an EU marketing authorisation for Elucirem„¢ (Gadopiclenol)with the indication of use for magnetic resonance imaging with contrast enhancement in...
Half-year results 2023 Acceleration of activity Half-year revenue: ‚¬378.6 million, up 2.8% at CER1Strong acceleration of activity in the second quarter, up 6.7% at CER Profitability in...
NEW YORK, July 20, 2023 (GLOBE NEWSWIRE) -- Betterguards, a next-generation sports technology innovator, announced today the unveiling of its newly launched U.S. product The BetterGuard during NBA...
Guerbet wins PI-CAI Grand Challenge on detection of prostate cancer Villepinte, 17 July 2023: Guerbet (FR0000032526 GBT), a global specialist in contrast media and medical imaging solutions, is...
Guerbet strengthens its Executive Committee with two new appointments to accelerate its commercial and industrial development Dan Raffi appointed Director of Commercial OperationsRaoul Bernhardt...
Changes in Guerbet's Board of Directors Appointment of Didier Izabel as Chair of the Board of DirectorsAppointment of Pascale Auger as an Independent DirectorRenewal of three directorships ...